인산 나트륨, 이염기성, 도데카수화물

인산 나트륨, 이염기성, 도데카수화물 속성

인산 나트륨, 이염기성, 도데카수화물 MSDS

Disodium phosphate dodecahydrate

인산 나트륨, 이염기성, 도데카수화물 C화학적 특성, 용도, 생산

물성

수용 액 은 약알카리성을 나타낸다. 알코올에는 불용. 물에는 가용.

용도

1. 청 관제, 탄철제, 피혁탄닝, 목제의 방부제
2. 범랑제조, 염색 매연제, 안료(침전제)
3. 의약 (페 니실린, 스트렙토 마이신의 제조)
4. 전분, 인산에스테르나트륨 제조에 사용
5. 완충작용이 강 하고 식품가공의 제조시 pH조정에 사용된다.
예를 들면 분유에서 용해도를 증가시키고 어육이나 식육의 반죽제품, 치이즈등은 다른 종합인산염과 병용하여 제품의 결착력을 향상시키는데 사용된 다.

화학적 성질

white crystals

용도

Sodium Phosphate Dibasic Dodecahydrate is used in method for preparing self-supporting membrane.

생산 방법

Either bone phosphate (bone ash), obtained by heating bones to whiteness, or the mineral phosphorite is used as a source of tribasic calcium phosphate, which is the starting material in the industrial production of dibasic sodium phosphate.
Tribasic calcium phosphate is finely ground and digested with sulfuric acid. This mixture is then leached with hot water and neutralized with sodium carbonate, and dibasic sodium phosphate is crystallized from the filtrate.

정의

ChEBI: A hydrate that is the dodecahydrate form of disodium hydrogenphosphate

일반 설명

Sodium phosphate is a colorless crystalline sodium salt. It is widely used as a buffer in molecular biology, biochemistry, and chromatographic studies. It exists in three forms: monobasic (NaH₂PO₄), dibasic (Na₂HPO₄), and tribasic (Na₃PO₄). Monobasic and dibasic forms in varying ratios are commonly used to compose the neutral sodium phosphate buffer solution.

Pharmaceutical Applications

Dibasic sodium phosphate is used in a wide variety of pharmaceutical formulations as a buffering agent and as a sequestering agent. Therapeutically, dibasic sodium phosphate is used as a mild laxative and in the treatment of hypophosphatemia.
Dibasic sodium phosphate is also used in food products; for example as an emulsifier in processed cheese.

Safety

Dibasic sodium phosphate is widely used as an excipient in parenteral, oral, and topical pharmaceutical formulations. Phosphate occurs extensively in the body and is involved in many physiological processes since it is the principal anion of intracellular fluid. Most foods contain adequate amounts of phosphate, making hypophosphatemia (phosphate deficiency) virtually unknown except for certain disease states or in patients receiving total parenteral nutrition. Treatment is usually by the oral administration of up to 100 mmol of phosphate daily.
Approximately two-thirds of ingested phosphate is absorbed from the gastrointestinal tract, virtually all of it being excreted in the urine, and the remainder is excreted in the feces.
Excessive administration of phosphate, particularly intravenously, rectally, or in patients with renal failure, can cause hyperphosphatemia that may lead to hypocalcemia or other severe electrolyte imbalances. Adverse effects occur less frequently following oral consumption, although phosphates act as mild saline laxatives when administered orally or rectally. Consequently, gastrointestinal disturbances including diarrhea, nausea, and vomiting may occur following the use of dibasic sodium phosphate as an excipient in oral formulations. However, the level of dibasic sodium phosphate used as an excipient in a pharmaceutical formulation is not usually associated with adverse effects.
LD50 (rat, oral): 17 g/kg

저장

The anhydrous form of dibasic sodium phosphate is hygroscopic. When heated to 40℃, the dodecahydrate fuses; at 100℃ it loses its water of crystallization; and at a dull-red heat (about 240℃) it is converted into the pyrophosphate, Na4P2O7. Aqueous solutions of dibasic sodium phosphate are stable and may be sterilized by autoclaving.
The bulk material should be stored in an airtight container, in a cool, dry place.

비 호환성

Dibasic sodium phosphate is incompatible with alkaloids, antipyrine, chloral hydrate, lead acetate, pyrogallol, resorcinol and calcium gluconate, and ciprofloxacin. Interaction between calcium and phosphate, leading to the formation of insoluble calcium-phosphate precipitates, is possible in parenteral admixtures.

Regulatory Status

GRAS listed. Accepted in Europe for use as a food additive. Included in the FDA Inactive Ingredients Database (injections; infusions; nasal, ophthalmic, oral, otic, topical, and vaginal preparations). Included in nonparenteral and parenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.

인산 나트륨, 이염기성, 도데카수화물 준비 용품 및 원자재

원자재

준비 용품

인산 나트륨, 이염기성, 도데카수화물 공급 업체

공급자	전화	이메일	국가	제품 수	이점
Chongqing Chuandong Chemical (Group) Co. Ltd.	+86-13637972665 +86-13637972665	wxc@cd1958.com	China	81	58
Hebei Yanxi Chemical Co., Ltd.	+8617531190177	peter@yan-xi.com	China	5993	58
Henan Bao Enluo International TradeCo.，LTD	+86-17331933971 +86-17331933971	deasea125996@gmail.com	China	2503	58
Hebei Saisier Technology Co., LTD	+86-18400010335 +86-13102810335	admin@hbsaisier.cn	China	892	58
Shaanxi TNJONE Pharmaceutical Co., Ltd	+8618740459177	sarah@tnjone.com	China	958	58
Jiangsu Kolod Food Ingredients Co.,Ltd.	+86-518-85110578 +8618805133257	sales3257@jskolod.com	China	132	60
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21691	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
Hefei TNJ Chemical Industry Co.,Ltd.	+86-0551-65418679 +86-18949832763	info@tnjchem.com	China	2989	55
Shanghai Zheyan Biotech Co., Ltd.	18017610038	zheyansh@163.com	CHINA	3620	58

인산 나트륨, 이염기성, 도데카수화물 관련 검색: